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Purpose:  Discuss current governance practices with federal biorepositories and provide 






Wendy Kaye, PhD 
Senior Epidemiologist, McKing Consulting Corporation 
National ALS Registry Program 
Agency for Toxic Substances & Disease Registry 
 
Dr. Kaye greeted participants, and requested that those present introduce themselves.  A list of 
meeting attendees is provided with this document as Attachment 1.  Following the introductions, 






Wendy Kaye, PhD 
Senior Epidemiologist, McKing Consulting Corporation 
National ALS Registry Program 
Agency for Toxic Substances & Disease Registry 
 
Dr. Kaye reported that the law to enact the National Amyotrophic Lateral Sclerosis (ALS) 
Registry was passed in October of 2008.  Under the law, the Centers for Disease Control and 
Prevention (CDC) and Agency for Toxic Substances & Disease Registry (ATSDR) are charged 
with establishing and maintaining a population-based ALS registry for the United States (US).  
However, the law does not make ALS a reportable disease.  The legislation specifies that the 
purposes of the ALS Registry are to describe the incidence and prevalence of ALS; describe the 
demographics of ALS patients; and examine risk factors for the disease. 
 
ATSDR has adopted a two-pronged approach for capturing ALS cases.  Existing national 
databases and an algorithm developed in a pilot study are used to identify true cases of ALS.  
The databases include the Veterans Benefits Administration (VBA), Veterans Health 
Administration (VHA), Medicare, and Medicaid.  The algorithm takes into consideration such 
elements as visits to a neurologist and a prescription for RILUTEK®.  The algorithm also 
identifies “potential ALS patients” in the national databases.  These persons are not included in 




National ALS Biorepository Pilot Study 
 




the National ALS Registry, and additional data are needed in order to determine whether they 
are true ALS patients.  ATSDR also created an Internet-based self-registration portal.  The 
portal captures patients who may not be in national databases, and allows participants to 
provide epidemiological data through surveys.   
 
No single study or database can answer all of the questions about ALS.  The registry aims to 
answer the following questions: 
 
 How many people actually have ALS?  
 What are the underlying genetic and environmental causes of ALS?  
 How can understanding these causes lead to prevention and treatment?  
 What biomarkers are useful for predicting disease progression and treatment 
responses? 
 
This information is assembled by integrating epidemiological data, clinical data, and basic 
research findings. 
 
A biorepository is a collection of biological specimens for future use.  The specimens can be 
applied to gene associations and environmental causes.  In the future, they could validate 
biomarkers and possibly lead to the discovery of underlying pathobiology. 
 
Several biorepositories are available for ALS researchers.  The Northeast ALS Consortium 
(NEALS), the National Institute of Neurological Disorders and Stroke (NINDS), the United States 
Department of Veterans Affairs (VA) Biorepository (VAB), the VA Brain Bank, and the Medical 
Research Council (MRC) Brain Bank for Neurodegenerative Diseases in London are examples 
of these resources. 
 
The National ALS Registry is currently in operation and a biorepository could enhance it by: 
 
 Correlating biomarkers with the extensive epidemiologic data collected by the National 
ALS Registry; 
 Enrolling a nationally representative, population-based sample of participants who are 
not selected by geographic area, exposure, or clinical characteristics; and 
 Increasing the number of biological specimens available for research on ALS. 
 
The goal of the National ALS Biorepository Pilot Study is to pilot methods for collecting and 
banking biological specimens from participants in the National ALS Registry.  Further, the pilot 
study will assess the potential for developing a comprehensive, national research resource that 
could be maintained in the long term.  The study’s objectives are to maximize scientific 
potential, given Registry parameters; maximize cost-efficiency; make recommendations for 
long-term sustainability; and recommend a process for providing access to the specimens to 
researchers. 
 
In March 2012, experts in ALS, biorepositories, and biomarkers convened at the National ALS 
Biorepository Expert Panel Meeting.  The group provided input regarding the draft ALS 
Biorepository Pilot Study protocol.  Among the discussion points were sample size and follow-
up, specimens to be collected by the biorepository, and the biorepository’s potential research 
uses.  The group suggested that the biospecimens collected from participants should 
complement the epidemiologic data in the National ALS Registry; allow comparisons with other 
studies; maximize scientific utility within Registry constraints; and be “future-proof;” that is, 
ensure that specimens are amenable to emerging technologies and research priorities. 





The National ALS Biorepository Pilot Study will collect specimens in participants’ homes and will 
enroll 300 participants for in-home collection.  Participants must be enrolled in the National ALS 
Registry and will be geographically diverse.  Specimens of blood, urine, hair, and nails will be 
collected at two time periods, six months apart.  Saliva will be collected if the blood draw fails.  
The order in which the blood specimens are to be drawn was determined by the constraints of 







tube Fractions Potential analyses (examples)
Blood
1 K2EDTA 1 10
White cells, red 
cells, plasma DNA, proteins, red cell lipids 
2 K2EDTA 1 4 Whole blood Lead, other metals
3 Plain 1 10 Serum Clinical biochemistries, metabolic products, other small molecules
4 PAXgene RNA 2 2.5  RNA-stabilized whole blood Intracellular RNA
Urine 9 -- Electrolytes, environmental chemicals, metabolic products, gut microbiome
Nail clippings -- -- Metals
Hair clippings -- -- Metals
Saliva* 2 -- DNA
The National ALS Registry Biorepository
Pilot Study: in-home collection 




The study will also enroll 30 participants for post-mortem collection.  As noted, these 
participants must be members of the National ALS Registry.  Their eligibility for the post-mortem 
collection must be confirmed by a treating neurologist, and they must be cognitively able to 
consent to participate in the study.  Further, they must not plan to be on a life support system, 
and their family members should be supportive of their participation in the study.  Because of 
the limited time frame of the study, persons with slow-progressing disease will not be eligible for 
post-mortem collection.  All materials must be retrieved by the end of the two-year study period, 
September 2015.  Post-mortem collection will include brain and spinal cord tissue, cerebrospinal 
fluid (CSF), muscle, and bone.  This aspect of the study will be conducted in collaboration with 
the Boston University Alzheimer’s Disease Brain Bank. 
 
The study protocol has received scientific clearance through ATSDR.  Dr. Rebecca Pentz, 
Professor of Research Ethics at Emory University School of Medicine, conducted an ethics 
review of the protocol and materials, especially for the post-mortem collection.  The Office of 
Management and Budget (OMB) granted a Clinical Exemption for data collection.  The protocol 
is undergoing Institutional Review Board (IRB) review.  Study staff are being hired, and 
participants will be recruited into the study beginning in mid-April 2013.  ATSDR is exploring the 




option of adding skin to the post-mortem collection.  If skin is added, a separate laboratory will 




• Dr. Kasarskis asked about consent issues associated with post-mortem collection.  In most 
states, the next of kin is legally responsible after a person dies. 
 
• Dr. Kaye responded that the pilot study will ask potential participants to indicate their 
understanding and interest in participating.  A family member will be asked to sign a 
“pledge” to agree to participate.  If the next of kin is not willing to participate, then the study 
will not retrieve the specimen. 
 
• Dr. Kowall reported that the Alzheimer’s Center at Boston University takes a similar 
approach.  The participant indicates intent to donate, and the family must be supportive. 
 
• Dr. Sorenson noted that participants will be self-identified and asked about plans if interest 
is significant and more people volunteer to participate than the 300 the study can 
accommodate. 
 
• Dr. Kaye answered that when people join the National ALS Registry, they have the option to 
check a box indicating their interest in studies for which they may be eligible.  The National 
ALS Biorepository Pilot Study will invite potential participants from that group for the in-home 
collection, and will ensure a geographically diverse population.  The selection algorithm will 
also allow for diversity among rural and urban areas.  The in-home collection will include 
Hawaii and Alaska, but the post-mortem collection will take place in the contiguous 48 states 
because of the 48-hour time limit for retrieving specimens.  There will be a notice on the 
ATSDR website when the pilot study opens, and there is potential for high interest. 
 
• Dr. Brooks emphasized that conducting the biorepository pilot project will “breathe great 
energy” into the National ALS Registry.  The method for rolling out the pilot study will be 
important.  Many ALS patients are likely to view the study as a much-needed and epic 
opportunity.  The advertisement of the project should emphasize the positive aspects of the 
study that will help the registry and should make the selection process clear. 
 
• Dr. Jenkins asked whether the same laboratory would be used for all of the in-home 
collections.   
 
• Dr. Kaye replied that Fisher BioServices will process and store all of the samples.  The 
same kit will be sent to all participants and used by the in-home nurse. 
 
• Dr. Kasarskis said that the process of obtaining in-home specimens worked well for the 
VAB.  The approach was convenient for patients, and there was a high acceptance rate.  
Their only struggle was in contracting national nursing entities with the proper research 
certifications. 
 
• Dr. Kaye said that the pilot study will utilize Phlebotomy Services International (PSI), a 
company that conducts studies for the National Institutes of Health (NIH) and other 
federally-funded agencies.  The company collects specimens all over the country and has 
strict requirements for their nurses and phlebotomists.  There will be ample time for the 
company to schedule the visits. 





• Dr. Horton agreed that the pilot study is a marketing opportunity for the National ALS 
Registry.  It is important that ATSDR and CDC make the most of this opportunity.  
Physicians and neurologists are also important communicators about the Registry, and the 
effort is collective. 
 
• Dr. Marcus asked about the enrollment and coverage of the National ALS Registry. 
 
• Dr. Kaye indicated that enrollment in the registry is strong.  Over half of the people who join 
the registry also complete surveys.  Dr. Horton added that the registry includes participants 
from all 50 states and US territories. 
 
• Given that the pilot study will not consent more than 30 participants for the post-mortem 
study, Dr. Bowser pointed out that they could potentially have zero post-mortem specimens.  
He asked about “fallback” plans, such as working with other organizations that collect tissue.  
It is likely that the next-of-kin will want to participate and will want to contribute tissue. 
 
• Dr. Kaye said that if the study period ends before all of the consented specimens are 
collected, they will provide lists of other banks that are interested in taking specimens, 
thereby creating linkages with patients and next-of-kin.  In creating the study protocol, they 
discussed at length the ethical considerations associated with consenting a person to 
participate and then not accepting specimens after September 2015. 
 
• Dr. Brady asked about the next steps beyond the pilot study, such as what will happen to 
the specimens if funding is not available to continue the National ALS Biorepository. 
 
• Dr. Kaye answered that the specimens will belong to ATSDR.  One of the study deliverables 
is to advise ATSDR on where the specimens should be stored.  ATSDR will maintain and 
distribute the specimens from the pilot study even if they cannot continue collecting 
specimens after the pilot phase. 
 
• Dr. Horton added that while future funding is not clear, there is good Congressional support 
for the National ALS Registry.  They are in a good position to conduct the pilot and 
determine the feasibility of a National ALS Biorepository. 
 
• Dr. Kaye said that in the future, the biorepository could be integrated into the National ALS 
Registry so that participants in the registry could indicate their willingness to contribute 
specimens up-front. 
 
• Dr. Kowall asked about disclosure to participants and contingency plans regarding the post-
mortem collection aspect of the study and noted that people will need to be recruited early in 
the study process.  In his experience, the length of illness can be longer than expected. 
 
• Dr. Kaye agreed and said that potential post-mortem participants will be recruited from 
persons who have been in the National ALS Registry for a longer period.  Further, the study 
will exclude slow-progressors and will incorporate consultations with the treating neurologist. 
 
• Dr. Marcus asked how the study will respond to potential volunteers for the post-mortem 
collection who are not likely to die within the study period. 
 




• Dr. Kaye answered that those persons will be told that they are ineligible for that aspect of 
the study.  Persons who indicate interest will sign a Health Insurance Portability and 
Accountability Act (HIPAA) waiver to allow for consultation with their neurologist.  A person 
could be ineligible for the post-mortem collection for several reasons, such as an indication 
of lack of family agreement. 
 
• Ms. Bledsoe said that if the specimens will potentially be transferred in the future, it is 
important that the HIPAA authorizations and informed consent forms are appropriately broad 
while remaining meaningful.  Some of these forms contain specific language about where 
specimens are stored, for instance. 
 
• Dr. Kaye said that the informed consent process stipulates that the specimens must be used 
for ALS research; there is no discussion of where they will be stored.  The specimens will 
also be de-identified when sent to researchers. 
 
• Dr. Lonsdale asked whether the informed consent process acknowledges the risk of 
identification through genotyping in the future. 
 
• Dr. Kaye replied that the possibility is not addressed.  The probability is low, because while 
DNA is a unique piece of information, it is not an identifier. 
 
• Dr. Pentz agreed that DNA is not an identifier at this point, as databases are not available to 
link genetic sequencing with individuals.  It could, however, be possible in the future. 
 
• Dr. Lonsdale indicated that sequences can be identified to the individual level. 
 
• Ms. Bledsoe added that there are arguments for including explicit statements in the informed 
consent package indicating that privacy cannot be guaranteed. 
 
• Dr. Lonsdale said that such language is included in the consent process for a National 
Cancer Institute (NCI) study.  The study will minimize the risk of identification, but the risk is 
present. 
 
• Dr. McQuillan said that an upcoming Institute of Medicine (IOM) workshop will address these 
questions as the science moves in this direction. 
 
• Dr. Boylan asked about criteria, such as length of disease, which may be applied to 
selecting participants for the in-home collection. 
 
• Dr. Kaye said that the criteria apply to ensuring that the group is diverse in age, geography, 
gender, and urban and rural locations.  That demographic information is available in the 
National ALS Registry.  RILUTEK® use is not a factor, as the data are not available in the 
Registry. 
  








Department of Veterans Affairs Biorepository and Brain Bank 
 
Marianne Bledsoe, MA 
Senior Program Manager for Biorepositories and Biobanking 
Biomedical Laboratory Research and Development 
Office of Research and Development 
United States Department of Veterans Affairs 
 
Ms. Bledsoe presented an overview of governance, data access, and distribution policies.  She 
reported that in their paper “Biobank Governance in the Post-genomic Age,” Gottweiss and 
Lauss define biobank governance broadly, focusing on the regulations of relationships between 
individual citizens, society, and biobanks.  Issues of consent, privacy, ownership, access, and 
benefit sharing are critical to governance.  Governance serves as a system of oversight.  Good 
governance is about responsible stewardship of valuable resources and ensuring that 
specimens are used for good science.  Legal and ethical issues are addressed to maintain the 
trust of participants and the public. 
 
Specimen and data access and distribution policies are elements of governance.  External 
governance mechanisms include factors that are generally not controllable, such as existing 
legislation and regulations, socio-cultural norms, funder requirements, scientific peer review, 
and ethics and privacy review.  Internal governance mechanisms can be controlled and include 
public engagement; scientific advisory and oversight committees and mechanisms; ethics 
advisory and oversight mechanisms; specimen and data storage and laboratory practices, 
which ensure quality; and specimen and data access. 
 
There are many models for biorepository governance.  One model includes a scientific advisory 
board that advises on the overall scientific direction of the project.  An executive or steering 
committee may manage the day-to-day operations and decision-making of the bank.  An IRB 
may be included, and a separate ethics advisory board could provide advice.  Other committees 
on biosafety, data safety, and other issues could be created.  Often, a specimen and data 
access committee makes decisions about how samples and data are used. 
 
VETERANS HEALTH ADMINISTRATION
Biorepository Governance:  One Model
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Governance of Existing Federal Biorepositories 
 




A biobank should document its access requirements as well as its review and dissemination 
policies thoroughly.  These requirements should address policies and procedures for 
determining what constitutes appropriate research uses of the specimens and data, both 
scientifically and ethically.  They should also address policies and procedures for prioritizing 
requests for access.  For example, some biorepositories give first priority to private researchers, 
second priority to unfunded pilot projects, and lower priority to for-profit entities.  Requirements 
for access to data may be less stringent than requirements for access to specimens because 
specimens are non-renewable resources with a finite lifespan.  These requirements will vary by 
biorepository and by specimen type.  
 
The process for access should be transparent, equitable, and free from conflicts of interest in 
the decision-making process.  The process should be published for the scientific community and 
for the research participants.  The rigor of the access requirements will vary according to the 
kind of biorepository.  Generally, the more scarce the resources, the more stringent the access 
requirements.  Good policies should be in place to ensure responsible access, and the policies 
should balance with the potential benefits and risks to participants and society.  Good review 
processes often improve the science. 
 
A number of considerations apply to reviewing requests for access.  Scientific considerations 
include the appropriateness of the proposed research use based on the purpose, nature, 
characteristics, limitations, and strengths of the repository.  These factors are seldom included 
in the review of a grant application, but they play an important role in reviewing access to 
biorepository specimens.  Other considerations include scientific merit and the potential impact 
of the proposed research; adequacy of the research design, particularly statistical issues; 
availability of funding for the research; experience and qualifications of the investigators; and 
adequacy of the research environment. 
 
A number of ethical considerations inform the appropriate use of specimens.  Benefits and risks 
to participants, populations, and society at large, are especially important.  Some of these 
issues are addressed by the IRB, but some issues may need to be reviewed as part of the 
request for access, especially regarding whether the proposed research use is consistent with 
informed consent.  In some cases, the research using the specimen will not be considered 
human subjects research, and there may be no requirement for IRB review.  Many repositories 
ask for documentation from the IRB that a proposed project is exempt from review.  When this 
review is required, regulatory approvals should be documented. 
 
When specimens and associated data are distributed, researchers should receive no identifying 
information.  Some information may be needed in some cases and should be addressed in the 
consent and authorization forms.  A strong Material Transfer Agreement (MTA), Cooperative 
Research and Development Agreement (CRADA), or other contractual agreement is extremely 
important to define the conditions of the use of the material. 
 
MTAs, CRADAs, and other contractual agreements may stipulate that the recipient of the 
specimens will not attempt to identify subjects; will abide by relevant regulations; will not sell or 
share the specimens and/or data with third parties; will only use the specimens and/or data for 
the proposed research use; will not use specimens for testing in humans; will follow appropriate 
biohazard precautions for handling specimens; will acknowledge the biorepository in 
publications, which helps the repository document its contributions and ultimately to get funding; 
will indemnify the biorepository; will abide by any collaborative agreements in place; will return 
research data to the biorepository if required; and will abide by any other conditions specified by 
the biorepository. 





The agreements may also include requirements for disposition of unused specimens or 
destruction of specimens and/or data at the end of the research period.  They may stipulate any 
intellectual property and publication rights of the providers of the specimens and/or data and the 
recipient researcher and/or institution. 
 
Ms. Bledsoe shared observations and experiences from the VA Biorepository Brain Bank 
(VABBB) ALS Bank.  The bank was established in 2006 and was recently opened for requests 
for access.  A number of issues were identified after one round of review, which included 
approximately 16 applications.  The VABBB assessed these concerns so that future requests 
for access will have a better chance of success.  Investigators whose applications were not 
approved were encouraged to reapply. 
 
Applications were frequently incomplete.  To address this problem, the VABBB triages the 
applications and clearly states on its website that incomplete applications will be delayed for 
review.  Many applicants described sample sizes that were too small and did not fully justify the 
sample size.  The VABBB now indicates in its processes that applications should provide 
justifications for the sample size and suggests that a biostatistician should be consulted as the 
application is created.  In some cases, the researchers lacked experience.  Some applications 
did not include sufficient detail regarding the proposed study.  The VABBB enhanced the 
application to address these problems.  Researchers in ALS frequently obtain samples from 
multiple sources, and some of the applications to the VABBB were not clear regarding the 
sources of additional samples and whether the samples would be available. 
 
Ms. Bledsoe shared the following “lessons learned” from the VABBB experience: 
 
 Make sure policies and procedures are well-established before entertaining tissue 
requests. 
 
 The biorepository should work closely with researchers in refining their requests before 
requests are submitted and evaluated. 
 
 If there has been preliminary data in human specimens, it should be included in tissue 
request applications. 
 
 Manage researcher expectations by explaining the policies and processes clearly. 
 
 Education and marketing are essential. 
 
 It may be necessary and desirable to refine policies and procedures based on 
experience and/or changes in science and ethical norms. 
 
 There is a “delicate balance” between ensuring that specimens are used appropriately 
and ensuring that they are used at all.  Finding the right balance can be difficult, 
especially with a scarce resource. 
 
  




Christopher Brady, PhD 
Director, Scientific Operations 
VA Biorepository 
VA Boston Healthcare System 
United States Department of Veterans Affairs 
 
Dr. Brady presented an overview of the VABBB, which is a multi-site brain bank.  Many of the 
bank operations, including clinical data collection and management, enrollment, coordination of 
tissue recovery, and diagnostic neuropathology, occur at VA Boston Healthcare System 
(VABHS).  Tissue is analyzed, processed, and stored at the Southern Arizona VA Healthcare 
System (SAVAHCS) in Tucson, Arizona.  The physical biorepository is located there as well.  
SAVAHCS coordinates tissue releases to investigators.  Tissue and data releases from the 
VABBB are ongoing. 
 
In designing its governance, VABBB wanted a transparent and understandable application and 
release process.  The governance design process included how reviews would be conducted 
and how the expert committee would be convened.  Finalizing the MTA was challenging 
because the VABBB has multiple sites that must sign off on the transfers.  Materials in support 
of committee functions, such as conflicts of interest, the charge to the committee, and review 
forms, were developed.  The process is a work in progress. 
 
The VABBB Tissue Access Committee includes a standing committee, comprised of ex officio 
members, that oversees the day-to-day work of conducting reviews.  The Access Committee 
also includes a number of subject matter experts who vote on the tissue requests.  The reviews 
are conducted via telephone in a manner similar to a grant review.  Many of the applicants to 
the VABBB have already been reviewed by NIH or another funding entity.  The VABBB 
committee does not serve as a second-level scientific review, but they are mindful of the amount 
of tissue that is being requested, given the limited resources in the bank.  There is frequent 
communication with the applicants after the review, whether the request is approved or 
disapproved.  The VABBB Tissue Access Committee is coordinated by the VA Central Office 
(VACO). 
 
After a request is approved, VABBB identifies the cases in the Tucson facility that will be 
selected for release, the clinical data that will be released, and archives of previous data 
collected by the National ALS Registry at the Durham, North Carolina VA facility.  VABBB also 





• Dr. Horton asked about the turnaround time from receipt of the application to shipping 
samples to the investigator. 
 
• Dr. Brady answered that the elapsed time depends upon the nature of the request.  The 
request is reviewed and receives approval or disapproval.  The VABBB then works with the 
investigator to coordinate transfer of the tissue.  If a case is simple and involves relatively 
few samples, it could be turned around within a month.  Some cases are more involved.  For 
instance, the VABBB has a process by which all genotyping data are returned to the 
biorepository, and those cases require more time and negotiation.  The VABBB does not 
need to involve the IRB. 
 




• Dr. Bruijn asked how many applicants were granted tissue samples, and about information 
regarding the projects that utilize the samples, publications, and any data sharing plans. 
 
• Ms. Bledsoe replied that they have not listed their researchers on their website.  The 
process has just begun, but VABBB expects to be notified of publications from the use of its 
specimens.  Because investigators do not always inform biorepositories about publications, 
some biorepositories ask for the information on a regular basis or search PubMed and other 
resources for information and then ask the investigator for verification. 
 
• Dr. Bowser co-chairs the NEALS biorepository and commented on similar issues that 
NEALS has experienced.  He and the other co-chair of the committee vet applications and 
work with the applicants to ensure that no information is missing.  NEALS includes biofluids 
and requires that applicants provide Quality Control (QC) information and reproducibility 
data, such as coefficient of variation (CV) values, for their chosen assays.  If applicants do 
not have these data, NEALS provides them with approximately 30 blinded samples to 
determine how well the assay performs.  If the assay performs well, then the applicant will 
receive samples; if not, NEALS provides the information to the applicant so that the assay 
can be improved.  Occasionally, investigators approach NEALS when they are submitting a 
grant application for a project that will utilize their samples.  In these cases, NEALS will 
provide the investigator with a letter of support that does not promise samples, but outlines 
the process for sample release. 
 
• Dr. Pentz said that in the future, results of research and publications should be expressed in 
lay terms so that participants in biorepositories and their family members can have access to 
them. 
 
• Ms. Bledsoe agreed and said that the VABBB newsletter summarizes projects that were 
approved. 
 
• Dr. Muravov noted that when the VABBB receives a specimen, it freezes half of the 
specimen for the future and reserves the other half for release.  He asked about the point at 
which the frozen part of the specimen would be used. 
 
• Dr. Brady confirmed that half of the specimen is frozen, and half is fixed.  The fixed half is 
analyzed at the Boston facility and is archived in Tucson.  The VABBB has the ability to 
distribute fixed or frozen tissue, depending on the request. 
 
National Institute of Neurological Disorders and Stroke 
The NINDS Repository: Policies to Facilitate Resource Sharing 
 
Roderick A. Corriveau, PhD (via telephone) 
Program Director, Extramural Research Program 
National Institutes of Health 
National Institute of Neurological Disorders and Stroke 
 
Dr. Corriveau explained that the mission of the NINDS repository is to accelerate discovery of 
causes and risks for neurological disease by sharing samples and data.  The repository was 
created in 2002, and many changes have occurred since then in policy as well as in a shift from 
renewable resources to non-renewable resources. 
 




NINDS placed a notice regarding the repository’s goals, use, and access.  Notice Number: 
NOT-NS-12-003 is available at http://grants.nih.gov/grants/guide/notice-files/NOT-NS-12-
003.html. 
 
Important policy issues for consideration include the following: 
 
 Access to samples, including submission of samples 
 Order evaluation and prioritization of orders 
 Material Transfer Agreements 
 Synergy through returned results and receiving information about samples 
 Sharing phenotypic and genotypic data 
 Lessons learned / looking forward 
 
With some exceptions, NINDS-funded investigators typically submit samples and data to the 
NINDS repository.  Terms and conditions of grant awards from NINDS may require sharing.  
Over time, they have learned to address consent issues early in the terms and conditions of the 
award and before IRB approval at the site.  This approach ensures sharing.  NINDS provides 
suggested and required consent language.  The repository institutes certain benefits for 
submitters, such as access to free or discounted samples. 
 
NINDS’s policy has been that samples and unidentified data are available to researchers at 
hospitals, universities, and commercial organizations.  When samples are distributed to 
commercial organizations, the MTA stipulates that the organizations may use the samples for 
their own internal research to generate knowledge.  That knowledge may be used to generate 
profit, but the samples and biological materials derived from them cannot be used for profit. 
 
The repository has traditionally housed mostly renewable resources, such as lymphoblastoid 
cell lines (LCLs) and DNA from LCLs.  Order evaluation and prioritization is relatively 
straightforward for these resources, and legitimate orders are filled.  As the repository has 
evolved to include more limited resources and questions have arisen regarding the utility of 
DNA from LCLs, the policies have changed.  A Biospecimen Access Committee (BAC) now 
evaluates applications for limited resources.  Some limited resources, such as DNA from whole 
blood, represent intermediate ground.  In these cases, a threshold has been established for the 
distribution to be evaluated by the BAC. 
 
In order to establish that the request is legitimate, the Principal Investigator (PI) and an 
institutional official authorized to make legal binding agreements must sign the MTA.  The PI 
must complete a statement of research intent.  For requests for renewable resources, this 
statement is a brief overview to indicate that the research is legitimate.  The MTA also 
addresses issues such as the destruction of samples after use, a promise not to attempt to 
identify the individuals from whom the samples were collected, and a prohibition of use of 
samples for human experimentation.  The MTA stipulates that materials will be used only for 
research, not for direct profit, and that secondary distribution must be approved by the NINDS.  
Secondary distribution has been an issue with induced pluripotent stem cells. 
 
NINDS works to achieve synergy through returned results to the repository.  Recipients are 
encouraged to report genotypic information to the repository so that the information can be 
listed with the samples and increase their value.  It is not easy to achieve this synergy, but 
benefits such as free or reduced-cost samples have been helpful. 
 




The NINDS repository was conceived to support genome-wide association studies.  When the 
repository was created, the Database of Genotypes and Phenotypes (dbGAP) did not exist, and 
there were few resources for sharing single nucleotide polymorphisms (SNP) data.  As studies 
were conducted with samples from the NINDS repository and SNP data became available, the 
repository created a SNP database.  The database was publicly accessible to investigators who 
applied for it through the Coriell database.  When the resource was available, 761 investigators 
registered for information from it, and at least 27 publications resulted from use of the data.  The 
publications focused almost exclusively on creating computational tools.  The SNP database 
was discontinued due to concerns about identification risks, and the information was shifted to 
dbGAP.  Data are still shared through dbGAP. 
 
In addition to SNP data, the NINDS repository has a strong history of sharing phenotypic data.  
The repository captures relatively few clinical data elements, but they are shared via the NINDS 
repository website.  A minimal clinical data set is available for all subjects in the repository.  
They are careful to maintain and monitor this resource as they balance a desire to make 
resources available and useful with a desire to respect the subjects in the repository and not to 
put them at unnecessary risk. 
 
To evaluate the impact of the resource, it is important to provide model acknowledgement 
language that investigators can use in their publications.  There can be a lack of leverage 
regarding acknowledging the resource and reporting publications.  Investigators should be 
reminded to provide information about publication, but it is also important to conduct ongoing 
literature searches for new papers or citations.  For obtaining data from investigators, time is of 
the essence to collect and share meaningful clinical data. 
 
“On demand” work for distribution can become a bottleneck.  For instance, if the repository waits 
for orders before aliquoting and performing QC, then the process can be quite slow.  Other 
major issues for a repository regard how to address the risk of de-identification and whether to 




• Dr. Horton asked about administrative fees for disseminating samples. 
 
• Dr. Corriveau answered that the NINDS repository does charge a fee, depending upon the 
sample type, which helps with cost recovery.  The cost also depends on whether a submitter 
asks for an embargo and whether the investigator will return high-value results to the 
repository.  The fee is minimal, and they may not charge a fee on future collections, such as 
biomarker discovery samples. 
 
• Dr. Brady answered that VABBB does not charge fees.  Ms. Bledsoe added that there are 
some constraints associated with a federal agency collecting fees. 
 
• Dr. Cwik asked about reporting requirements at the end of the project for which the samples 
were used, especially since many results may not be published. 
 
• Dr. Corriveau said that the MTA from the NINDS repository requires that unused samples 
are returned.  There is not an explicit requirement for a report on a project if there is no 
publication. 
 




• Dr. Brady said that the VABBB approach is similar.  They do not ask for formal progress 
reports, but they have discussed the idea.  Ms. Bledsoe said that some repositories send 
annual inquiries to investigators who have received tissue.  The inquiry asks for updates on 
research results and publications, as well as data about the investigators’ satisfaction with 
the resource.  This annual information collection is a broader opportunity for feedback on the 
samples than the questionnaire that is initially sent with the samples. 
 
• Dr. Lonsdale added that the National Disease Research Interchange (NDRI) serves 
approximately 600 investigators per year.  They send a QA form with each shipment and 
conduct an annual, web-based QA to get information about the samples as well as 
publications and conferences. 
 
National Center for Birth Defects and Developmental Disabilities 
National Birth Defects Prevention Study Biorepository Governance 
 
Mary Jenkins, PhD 
National Birth Defects Prevention Study Biologics Coordinator 
National Center on Birth Defects and Developmental Disabilities 
Centers for Disease Control and Prevention 
 
Dr. Jenkins reported that in 1996, Congress mandated the establishment of Centers for Birth 
Defects Research and Prevention.  CDC funded these centers through cooperative agreements 
in five-year cycles.  All of the centers collaborate on the National Birth Defects Prevention Study 
(NBDPS).  There have been 10 centers over time in geographically diverse areas. 
 
The NBDPS is a population-based, case-control study of approximately 30 major structural birth 
defects.  The study focuses on defects with unknown etiology and includes infants born 
between October 1997 and December 2011.  The three main components of the study are case 
ascertainment, maternal interview, and DNA collection. 
 
After mothers are interviewed, they receive a cheek cell collection kit.  The study collects buccal 
cells using two cytobrushes each from the mother, father, and infant.  One of the cytobrushes 
remains with the local center, and the other brush is returned to the repository.   
 
The DNA collection has changed over the years of the study.  From 1997-2003, each center 
conducted its own DNA extraction and QC.  They sent the aliquots to the repository, which was 
at CDC at CDC/ATSDR Specimen Packaging, Inventory and Repository (CASPIR).  In 2003, 
the study shifted to the NBDPS Central lab at CDC, which has helped with the standardization 
of samples that are sent to the repository.  In 2011, the study outgrew CASPIR and experienced 
a freezer failure, so the samples were moved from CASPIR to Fisher BioServices. 
 
Most of the samples at the NBDPS Biorepository are available for distribution, but some are 
unavailable because they failed QC.  Samples are only released to NBDPS researchers at one 
of the 10 center laboratories.  Aliquots may also be shipped out of the biorepository to center 
laboratories because the family has become ineligible or to the NBDPS Central lab for 
subaliquoting.  Aliquots may be destroyed if they become ineligible or re-labeled if a control 
infant is later diagnosed with a birth defect. 
 
NBDPS has a Coordinating Council, which is composed of each center’s PIs.  The council is the 
decision-making body that oversees the entire study.  A Data Sharing Committee is composed 
of two members per center.  This body reviews letters of intent and proposals requesting 




specimens and data.  The brief letters of intent must be approved before the detailed proposal is 
submitted.  The Data Sharing Committee also reviews abstracts and manuscripts resulting from 
analyses of non-genetic and genetic data from the NBDPS.  Other bodies include the Biologics 
Committee and the Genetic Analysis Working Group, which provide information for the Data 
Sharing Guidelines and support for requests for DNA analysis. 
 
The application process for samples from the NBDPS Biorepository is relatively closed.  
Investigators from outside the NBDPS must collaborate with a sponsoring PI from one of the 
centers.  Each center PI is responsible for confidentiality and data use oaths.  Letters of intent 
and proposals are submitted to the Data Sharing Committee for review.  The Data Sharing 
Committee evaluates all project proposals according to the same criteria, which include whether 
the analyses are reasonable, power calculations, plans for biologics and other expertise, and 
conflicts with existing proposals.  The Data Sharing Guidelines include requirements for project 
approval. 
 
Proposals involving DNA analysis must undergo an additional review.  Those projects are 
reviewed for the following aspects: 
 
 Provision of relevant preliminary data  
 Laboratories that will analyze the DNA specimens must pass an external QA 
 Overlap with other projects 
 Review of genes by the IRB 
 
The external QA of the laboratories utilizes pre-characterized samples.  The laboratories apply 
the proposed methods to the samples and return them to CDC.  Matrices are maintained to limit 
overlap of projects. 
 
When the NBDPS was established, it was impossible to know which genes would be studied.   
The IRB approved submission of “gene one-pager” forms.  The form addresses whether 
disease-causing allelic variants of the gene are known, and whether the proposed test will 
identify them.  If so, the test must be completed in a Clinical Laboratory Improvement 
Amendments (CLIA)-certified laboratory so that the results can be reported to individuals. 
 
Following approval of a proposal by the Data Sharing Committee and approval of gene one-
pagers by the CDC IRB, investigators submit a “Request for Biorepository Samples” form.  The 
form verifies a sponsoring PI and other relevant information.  Investigators must review the 
interview status to ensure that they have useful information.  Each of the aliquots is allotted to 
one of the centers, so they must confirm that the center has not previously requested all of their 
allotted samples.  Investigators confirm that samples from their own center have not been 
requested. 
 
The agreement, which must be signed by the requesting investigator and sponsoring PI, states 
that the DNA will be stored securely by the center.  Results of the project will be transmitted 
within two months to the genotyping database, and the study must be completed within three 
years of requesting the samples. 
 
CDC cooperative agreements do not fund genetic analysis; they only fund collection of samples.  
Therefore, each center obtains its own funding for analysis.  Because the group is of limited 
size, prioritization for sample requests has been on a first-come first-served basis.  The process 
can be modified based on timelines of funding agency requirements. 
 




Before samples are distributed, sample requests are reviewed and verified at CDC.  If 
specimens need to be aliquoted, the central laboratory performs the sub-aliquoting and sends 
the specimens back to the repository for distribution.  A list of available aliquots is created and 
shared with the lead investigator via a Secure Data Network.  Only CDC Data Curators can 
request samples from the repository.  Final requests are submitted to the repository via a secure 
File Transfer Protocol (FTP) site.  The aliquots are shipped directly to the laboratory designated 
by the requesting center. 
 
Typically, results are transmitted to the genotyping database after the publication is released.  
This approach eliminates any embargo period.  Data submission and publications are tracked 
through annual data sharing updates.  Lead investigators update their projects annually.  If they 
do not update the project, then it can be terminated and another investigator can lead it.  Data 
will be released annually to NBDPS collaborators. 
 
Among the lessons learned by the NBDPS is the importance of centralizing sample processing.  
It is also important to choose the repository carefully and ensure that the following are in place: 
equipment QC, contingency plans and back-up storage space, data QC and inventory 
management, and responsiveness. 
 
Creating two aliquots per specimen saves storage space.  Separate small freezer units are 
preferable to a single large unit.  Data management is also important, and their process includes 
monthly snapshots of inventory and monthly review of shipping, re-labeling, and destruction 
reports. 
 
The NBDPS is ending, and a new case-control birth defects study, the Birth Defects Study to 
Evaluate Pregnancy exposureS (BD-STEPS), is beginning.  The new study will not collect 
samples via cytobrush, but will collect saliva instead.  The new study will use repository-only 
aliquots, and they hope to utilize a single IRB.  Broad data sharing will be included in the 
consent form.  Data have not yet been submitted to dbGaP, but the sharing of aggregate data is 




• Dr. Antao asked who CDC Curators are.  Dr. Jenkins answered that only she and the PI of 
the study can request samples for other people. 
 
• Ms. Bledsoe asked about the policy regarding returning individual research results to 
participants, particularly with regard to how samples are verified.  There is a great deal of 
debate on this topic. 
 
• Dr. Jenkins said that the study has not yet returned results, as no clinically significant 
studies have been completed.  Because of the potential for clinically significant variants, a 
process is in place.  Aggregate results will be reported via an annual newsletter.  If 
participants want their individual information, they can request it.  A clinical geneticist at 
each center will report results to participants.  Any studies that are determined to be 
clinically significant must be completed in a CLIA-certified laboratory.  Participants are 
informed that any results should be verified with their healthcare providers. 
 
• Dr. Marcus asked how studies are determined to be clinically significant. 
 




• Dr. Jenkins said that in one proposed study, investigators plan to study a chromosome 
deletion that is known to be clinically significant.  Many people would have been diagnosed 
with the deletion before the study was complete.  If they have not been diagnosed, how 
important is it for them to know it?  This deletion is potentially significant for reproductive 
reasons, so it is a clear-cut decision.  Other decisions are less clear.  For instance, a gene 
may have disease-causing variants, but the proposed study may not identify them.  The 
gene one-pager allows for assessment of the information on a case-by-case basis.  The 
process for determining whether information should be returned includes several layers of 
review, including review by clinical geneticists at the center. 
 
• Ms. Bledsoe noted a paper describing the experiences of NBDPS would be a great addition 
to the field.  Dr. Jenkins hoped that those “lessons learned” would be part of the literature 
generated as the NBDPS comes to an end. 
 
National Health and Nutrition Examination Survey 
The NHANES Biorepository Program 
 
Geraldine McQuillan, PhD 
Senior Infectious Disease Epidemiologist 
Division of Health and Nutrition Examination Surveys 
National Center for Health Statistics 
Centers for Disease Control and Prevention 
 
Dr. McQuillan presented an overview of the National Health and Nutrition Examination Survey 
(NHANES) Biorepository Program.  NHANES is a probability sample of the US population, with 
5000 US residents per year sampled from a variety of households in 15 counties in the US.  
When persons are selected, they are asked to sign a separate consent for the collection and 
storage of blood and urine for use in future studies.  They are also asked to consent to the 
collection of DNA for genetic studies if they are 20 years old or older. 
 
Blood is collected at a mobile examination center.  Some of the blood is stored at CDC in 
CASPIR.  These samples are pristine.  They have never been frozen or thawed.  CASPIR 
includes samples from NHANES 3, which was conducted from 1988 through 1994, and samples 
from 1999 through 2013.  NHANES became a continuous survey in 1999.  Over two million 
samples are stored in CASPIR.  Unfortunately, CASPIR has no more space to receive 
additional samples, so other repositories are needed. 
 
Other blood samples from the NHANES mobile examination centers are sent to one of CDC’s 
28 laboratories.  Surplus sera that are returned are stored in a residual bank in Frederick, 
Maryland.  Over 300,000 samples from 1999 through 2010 that have been previously thawed 
are stored in this bank.  They are an excellent resource for future studies. 
 
  




Researchers may submit proposals to use NHANES specimens on a rolling basis.  Proposal 
guidelines are on the Web at http://www.cdc.gov/nchs/nhanes/genetics/stored_specimens.htm.  
The review process includes a technical review panel and IRB review.  Samples are released 
only after a study is approved at a cost per vial of $8.50. 
 
Proposals are emailed to Dr. McQuillan, who forwards them to the Stored Specimen Technical 
Panel.  The panel includes a clinical pathologist, a pediatrician/epidemiologist, a survey analyst 
with a nutrition and laboratory background, a university professor with laboratory background, a 
statistician, and other subject matter experts as needed.  Because proposals are accepted on a 
rolling basis, protocols are not prioritized.  It is important to public health to be responsive to 
requests.  If the research is considered worthwhile, it is accepted. 
 
The criteria for accepting proposals include the following: 
 
 Specific aims are stated, with the hypotheses to be tested. 
 Background and public health significance are clearly stated, and are supported by 
existing literature. 
 Research design and methods are included that demonstrate a working knowledge of 
procedures required for laboratory assays, and assays are state-of-the-art and validated. 
 An acceptable analytical plan demonstrates knowledge of the NHANES design and 
weighting issues.  NHANES is a complex design that over-samples various populations 
in order to provide more precise estimates for minority groups, and many proposals do 
not include sufficient analytic processes. 
 Appropriate experience and qualifications of the investigators are included. 
 
Dr. McQuillan creates a summary statement based on the evaluations from the technical panel.  
The statement addresses the proposal’s major strengths and weaknesses as expressed by the 
reviewers.  The investigators are asked to respond to the identified weaknesses, and the 
responses are returned to the technical panel.  If the panel concludes that the investigators 
have addressed the weaknesses satisfactorily, then the protocol is approved.  Dr. McQuillan 
sends a packet of information, including the summary statement and protocol, to the Associate 
Director for Science for review.  The package is also reviewed by the Confidentiality Officer and 
the IRB.  CDC’s IRB approval is necessary for the shipment of specimens. 
 
Upon approval, the investigator chooses samples by looking at the public-use files.  The 
investigator then sends an Excel spreadsheet to the National Center for Health Statistics 
(NCHS) with the sequence identifications (IDs) of the corresponding vials of serum.  Samples 
are available for those aged six and up.  This spreadsheet is matched to the consent file to 
ensure that the individual has provided appropriate consent.  The in-house IDs are matched to 
the inventory from the contract repository or CASPIR.  A final “pull” file is created, and the 
samples are pulled and sent with only the in-house ID. 
 
An Interagency Agreement or an invoice is sent to cover the cost of pulling the specimens.  An 
MTA is signed by the PI and the director of the laboratory who is handling the specimen.  The 
MTA addresses the use of the specimens. 
 
All results from research from a stored specimen project are returned to NCHS.  The 
investigator only has the in-house ID, so the materials must be returned to be linked to the 
public-use sequence number in order to conduct analysis.  The investigator then has 60 days 
for QC.  The data cannot be presented or published until the QC period has been completed 




and the data has been released to the public.  The time period has been sufficient, and 
investigators have not complained about the process. 
 
Dr. McQuillan shared the following “lessons learned” from the NHANES Biorepository: 
 
 Careful consideration should be given to the test results from future research studies 
that should be reported back to participants and how this will be done. 
 
 Make sure investigators, especially technicians, do not change labels when they run 
your samples.  An investigator removed the NHANES label on a set of samples, making 
the re-linking the samples to the public-use sequence a nightmare. 
 
 Investigators can greatly add to the value of NHANES by using stored specimens.  They 
can take advantage of future technology, respond to new outbreaks, and define the pre- 
and post-prevalence of an infection.  They can evaluate the efficacy of a vaccine 





 Dr. Horton asked how soon applicants can receive samples from the NHANES 
Biorepository. 
 
 Dr. McQuillan answered that proposals are accepted on a rolling basis.  She vets them first, 
and if the applications are complete, she sends them to the technical panel immediately.  
The panel has two weeks to review the applications.  If the proposal is approved, the 
samples could be released in approximately one to two months. 
 
 Dr. Brooks asked how many proposals per year are approved. 
 
 Dr. McQuillan said that NHANES is limited because the projects conducted with NHANES 
data cannot be actionable, as results are not returned.  Therefore, the types of research that 
are conducted are narrow and not clinically relevant.  Approximately 10 to 15 proposals per 
year are approved, and many more would be possible without that limitation.  Further, 
NHANES does not advertise very well.  She and one programmer are the only staff devoted 
to the biorepository.  She would like to see 20 to 30 proposals approved per year, but the 
increase in volume would require more staff and more advertising. 
 
 Dr. Horton asked whether it was difficult to collect fees for the samples. 
 
 Dr. McQuillan answered that they had no difficulties, as they publicize the fees and justify 
them.  She created a table to illustrate the costs associated with preparing the samples, the 
vials, and costs to the repository.  She has not experienced any issues with the fees or with 
increasing them when necessary. 
 
 Mr. Hixon said that BioFisher supports various models for cost reimbursement, from cost 
recovery to the cost of shipping. 
  









Marta Gwinn, MD, MPH 
Senior Consultant for Epidemiology 
McKing Consulting Corporation 
Centers for Disease Control and Prevention 
 
Dr. Gwinn thanked the group for attending and participating in the discussion.  She presented 
the current draft governance for the National ALS Biorepository Pilot Study, explaining that the 
goal of the National ALS Biorepository is to provide a resource for research that will contribute 
to better prevention and treatment of ALS.  The resource should be population-based and 
nationally representative, like the National ALS Registry; integrated with epidemiologic 
information collected by the National ALS Registry; based on informed consent by research 
participants; and publicly available to ALS researchers. 
 
The purpose of the pilot study is to develop and test procedures for enrolling participants, 
collecting specimens, and storing samples in the biorepositories.  In-home collections will occur 
of blood, urine, hair, and nails.  A separate program will collect brain and spinal cord, CSF, 
muscle, and bone post-mortem.  The pilot study will also propose guidelines for the release and 
use of samples for research; however, the pilot study does not include implementing and testing 
the guidelines; calling for and reviewing research proposals; or distributing samples for 
research. 
 
The goals of the guidelines are to encourage use of the biorepository for relevant research; 
assure and facilitate researcher access to the samples and registry data; assure that public 
presentations of findings are accurate and objective; establish guidelines for authorship and 
acknowledgement of the resource; and maintain a record of proposed and published research. 
 
Dr. Gwinn described the proposed National ALS Biorepository Research Committee, or “Core 
Committee,” which is based on ATSDR’s draft guidelines for use of the National ALS Registry 
data.  The National ALS Registry Research Committee governs the use of registry data for 
epidemiologic analysis and for recruiting participants for other studies such as surveys or clinical 
trials.  The committee members are appointed by ATSDR to serve two-year terms.  A committee 
chair is elected by members. 
 
The Core Committee consists of three researchers or clinical care providers, one lay patient 
advocate, one ethicist, two members of ATSDR’s ALS program, the Associate Director for 
Science of the ATSDR Division that houses the registry, and an additional person appointed by 
that division’s director.  The Associate Director and person that he or she appoints are not 
voting members of the committee. 
 
The proposed Biorepository Research Committee structure adds two supplementary voting 
members:  one laboratory-based ALS researcher and one laboratory scientist with knowledge of 
laboratory procedures and QC.  The Biorepository Research Committee will be supported by 
ATSDR and an Executive Secretary.  It is proposed that the committee review research 
proposals twice annually, following announcements in the Federal Register. 
 
Presentation of Governance for National ALS Biorepository Pilot Study 
 




The research application will require the investigator’s contact information and a brief summary 
of the proposed research.  It will include the funding source, potential conflicts of interest, and 
an IRB determination.  Researchers requesting samples and data will also be asked to provide 
a cover letter explaining the nature of the research, a biosketch or curriculum vitae (CV) of the 
PI, a copy of the full study protocol, documentation of IRB approval or exception, and a sample 
request sheet.  These materials can be submitted online via an ATSDR portal. 
 
Before the committee meets, the Executive Secretary will review the submitted applications for 
completeness.  The Executive Secretary will complete a Review and Score Sheet and will 
document other information, such as whether the investigator has applied previously.  The 
Executive Secretary will assign full review of the application to two voting committee members, 
including at least one of the laboratory scientist supplementary members.  Application materials 
will be distributed to all members of the Biorepository Research Committee.  The committee 
members will read each application, and the reviewers will complete Section 2 of the Review 
and Score Sheet, which includes the score criteria. 
 
The research proposal review criteria are as follows: 
 
 Is the protocol scientifically valid?  
 Will the study add to existing scientific information on ALS?  
 Do the investigators demonstrate capacity to complete the proposed research? 
 Does the protocol include adequate protections of confidentiality? 
 
Approval of a proposal requires a score of at least 3 on each criterion.  When the committee 
meets, either virtually or in person, the assigned reviewers will present the application and lead 
the subsequent discussion.  Voting committee members will vote to approve or deny the 
application and will agree on the final score.  The committee chair will submit the Committee 
decisions and scores to ATSDR. 
 
ATSDR will make its determination and respond to the PIs.  The PIs will be notified regarding 
whether their project is approved and whether it is high priority.  If so, they will receive a project 
number and will complete the Confidentiality and Data Use Agreement and MTA.  If the project 
is denied, the PI may resubmit it one time.  The PIs are also responsible for an annual Project 
Update. 
 
The Confidentiality and Data Use Agreement includes the following provisions: 
 
 Protect confidentiality by not linking biorepository records with identifiable data such as 
medical records and by restricting and tracking access to samples and data within the 
facility. 
 
 Respect ATSDR control of samples and data, acknowledging that ATSDR must approve 
all uses of the materials.  PIs will not share samples or data with other investigators and 
will delete data files when the project is completed. 
 
 Abstracts and manuscripts will be submitted ATSDR for review.  Abstracts should be 
submitted two weeks in advance of presentation, and manuscripts should be submitted 
four weeks in advance of submission. 
 
  




The MTA is standard to the Public Health Service (PHS).  It details that materials cannot be 
used in humans or commercialized; materials can be used only for the specified project without 
sharing; the recipient (investigator) of the materials retains patent and intellectual property 
rights; the provider (ATSDR) must be acknowledged in presentations and publications; and 
endorsement by the government may not be implied. 
 
All projects must provide an annual update.  The update should indicate any changes in 
investigators and report on the status of the project.  Completion or termination of the project will 
lead to questions regarding return of the samples and data.  The update also asks for a list of 
publications and presentations.  There is also a provision for terminating the project if the 
update is not provided by a specified date. 
 
ATSDR is responsible for announcing availability of samples from the biorepository in the 
Federal Register.  ATSDR is also responsible for administering the review committee and 
prioritizing applications after the scores are submitted.  ATSDR releases the samples and data 
and monitors research progress and products. 
 
The investigator obligations include agreeing to the Data Use and Confidentiality and MTA 
requirements.  The investigator will also agree to send abstracts and manuscripts to ATSDR for 
review; to submit annual progress reports; and to report publications.  The investigator is also 
responsible for returning residual samples and deleting files at the end of the project. 
 
Additional investigator activities could include releasing research data to the biorepository to 
build synergy and the knowledge base associated with each sample.  Additional ATSDR 
activities could include sharing information about active and completed projects online or 
sharing research data with other investigators. 
 
Dr. Gwinn thanked Dr. Vinicius Antao, Dr. Mary Jenkins, Dr. Rod Corriveau, and Dr. Geraldine 




• Dr. Bruijn commented that the guidelines include a requirement that data will not be shared 
with other researchers until 12 months after the original publication, which seems like a long 
time.  Dr. Gwinn agreed and noted that the NHANES requirement is only 60 days. 
 
• Dr. McQuillan asked about any human subjects concerns that should be addressed.  Dr. 
Kaye answered that IRB and human subjects considerations are part of the specimen 
collection, but not sample distribution, as the samples will be de-identified.  ATSDR will be 
able to link the specimens, but as long as the linkage is not provided to recipients of the 
samples, there are no IRB issues. 
 
• Dr. McQuillan cautioned that human subjects considerations may need to be revisited, since 
ATSDR can link the information to individuals. 
 
• Stressing that it is important to be upfront about the process and the possible outcomes, Dr. 
Gubitz asked what it means when an application is scored as “low priority.”  Do the 
investigators have to wait longer for samples, or do they receive fewer samples?   
  





• Mr. Handsfield recommended that ATSDR consider whether deleting data at the end of the 
study may violate the Federal Records Act and its requirements pertaining to funding and 
data maintenance.  Data retention requirements can be up to 20 years.  Ms. Bledsoe said 






Wendy Kaye, PhD 
Senior Epidemiologist, McKing Consulting Corporation 
National ALS Registry Program 
Agency for Toxic Substances & Disease Registry 
 
The group discussed a series of questions pertaining to the National ALS Biorepository and its 
governance.  Detailed discussion points are documented following the question within which 
they were raised: 
 
Who Should Be Allowed to Request Specimens from the Biorepository? 
 
• Ms. Bledsoe suggested that any qualified ALS researcher, from academia or industry, 
should be allowed to request specimens. 
 
• Dr. Bruijn said that they may not want to limit access to ALS researchers alone, but that an 
ALS researcher should be a collaborator or partner on the project.  For instance, a marker 
that overlaps Parkinson’s Disease and ALS could bring value to the field. 
 
• Dr. Kowall said that not restricting applicants to researchers with “a track record in ALS” 
could encourage pilot studies and new ideas. 
 
• Dr. Sorenson added that any proposal that addresses ALS is, by default, from an ALS 
researcher. 
 
• Dr. Marcus noted that Dr. Corriveau’s presentation addressed the question of consent and 
whether limiting the release of specimens to ALS research may be too narrow.  For 
example, a research project on neurodegenerative disease from an expert in Parkinson’s 
Disease could incorporate a hypothesis about common pathways.  She encouraged a broad 
view of what is relevant to ALS. 
 
• Dr. Kaye clarified that the Registry is Congressionally mandated to conduct work specific to 
ALS.  It will be important to understand whether specimens collected under this mandate 
could be used for research other than ALS research. 
 
• Dr. Kasarskis said that the guidelines for the review panel could address this question so 
that the review panel will keep the priorities of the bioregistry on track.  ATSDR will have the 
final say regarding who will receive specimens. 
 
• Dr. Horton asked the group whether American researchers should have priority over 
European researchers who request specimens. 
 
Discussion of National ALS Biorepository Governance 
 




• Dr. Bruijn felt that the biorepository should be international.  Researchers from different 
countries collaborate on many initiatives and programs. 
 
• Ms. Bledsoe added that many other sources of ALS specimens come from researchers 
outside the US, so it is important that those researchers are allowed access to the National 
ALS Biorepository samples. 
 
• Dr. Cwik agreed and added that because ALS is a rare disease, it is important to have as 
many samples as possible and to give as many researchers as possible access to them. 
 
• Mr. Handsfield asked whether the biorepository should be open for surveillance work, given 
that according to federal rules, surveillance is not research and surveillance systems do not 
require IRB review. 
 
• Dr. Kowall said that if a surveillance-related project would advance the science of ALS, then 
it could be considered. 
 
What Type of Analyses Can Be Done? 
 
• Dr. Gwinn asked about governance regarding the ways that the samples could be used, 
which will impact the types of scientists that might apply for them.  Other biorepositories 
require that applicants requesting samples provide data on the performance of their chosen 
assays.  Research to develop assays for ALS would be relevant and state-of-the-art.  She 
wondered how to balance the value of the National ALS Biorepository samples as another 
source to be combined with other samples with its intrinsic value as a population-based, 
nationally representative sample. 
 
• Dr. Bruijn recommended that the governance should not be too proscriptive.  The scientific 
review will determine whether the proposals are the best use of the biorepository samples. 
 
• Dr. Kasarskis agreed.  Science and technology move fast, and the governance should leave 
it open, allowing the scientific panel determine the merit of the proposals. 
 
• Dr. Bowser agreed, but noted that the review committee might consider sending test 
samples to evaluate performance when proposed assays look promising but have not been 
validated.  The test is a form of QC that ensures that the samples will not be wasted. 
 
• Ms. Bledsoe said that the negotiations with the researchers could incorporate this approach.  
The review committee could approve a pilot study with a few test samples, and then the 
investigators could return the data in order to get more samples. 
 
When Can Samples Be Requested? 
 
• Dr. Bruijn supported a process for reviewing requests on an ongoing basis as they are 
submitted.  Specific time periods are too restrictive.  Reviews can be conducted via email 
and telephone, and the process can be flexible. 
 
• Ms. Bledsoe mentioned the need to let the collection “mature.”  At what time will there be 
sufficient numbers of cases with sufficient data? 
 




• Dr. Kowall said that a flexible review process will be important for funded investigators for 
whom “the clock is ticking.”  Review committees can meet via phone or via virtual 
conferences on the Internet. 
 
• Dr. Boylan added that a restrictive review process may discourage investigators.  If there is 
a long lag time, investigators may bypass this resource. 
 
When Will The Samples Be Available? 
 
• Dr. Cwik noted that distributing samples is not part of the pilot study protocol and asked 
when the samples will be available. 
 
• Dr. Kaye answered that the contract ends in September 2015, at which point all specimens 
will be collected. 
 
• Dr. Horton said that prior to the end of the contract; ATSDR will decide whether a full-
fledged biorepository is possible.  If so, it is likely that another group will be contracted to 
administer it.  It may be possible to use the pilot samples to populate the full biorepository.  
They will need a sufficient amount of samples in order to move forward, and a plan will be in 
place before the end of the contract. 
 
• Dr. McQuillan indicated that she is the only person who handles the distribution of the 
NHANES samples. 
 
• Dr. Kaye reminded everyone that the 300 blood specimens would be representative of the 
National ALS Repository, and agreed that there could be problems if samples are distributed 
before the collection is complete and fully representative. 
 
• Dr. Gubitz recommended that when the collection phase is complete, ATSDR should 
announce the contents and availability of the biorepository.  The announcement should also 
explain the process for requesting samples. 
 
• Dr. Brady suggested that if there is a possibility that the samples will be transferred after 
they are collected, the informed consent form should take that possibility into account. 
 
• Dr. Kaye said that the location of the samples will not be specified.  ATSDR will own the 
samples and can store them at a CDC facility or a contract facility. 
 
• Dr. Kasarskis reinforced the need to manage the expectations of the research community, 
emphasizing the importance of not over-promising and then not being able to deliver on 
those promises.  Over-promising could result in the research community becoming 
disenchanted.  The research community will be eager to utilize the samples, but this pilot 
study is elaborate and broad, encompassing many issues and methods regarding data 
management, processing, consent, and collection. 
 
• Dr. Kaye stressed that the pilot study also aims to collect specimens that will be useful even 
if ATSDR does not go forward with the bioregistry for some reason. 
  





How to Request Samples 
 
• Dr. Kaye reminded the group that the preliminary process for requesting samples includes a 
7000-character project summary, the IRB-approved protocol, proof of IRB review, 
investigators’ CVs, and issues related to conflicts of interest.  She asked whether applicants 
should provide additional information. 
 
• Ms. Bledsoe wondered whether a full study protocol is needed.  In many cases, a peer 
review of the project will already have been conducted.  A summary, or a slightly-expanded 
summary, of the project may be sufficient for evaluation. 
 
• Dr. Lonsdale agreed and added that NDRI does not require the full study protocol.  
Investigators provide a technical summary as well as a lay summary, which is provided to 
the source of the tissue and the family. 
 
• Ms. Bledsoe said that the VA requests information such as preliminary data, statistical 
analysis, and support for the tissue that is being requested. 
 
• Dr. Bruijn suggested that comments from the peer review could be submitted. 
 
• Dr. Lonsdale reported that NDRI collects that information for NIH awards when it is 
appropriate. 
 
• Dr. Gubitz indicated that when NIH awards are made, the information (investigator name, 
institution, grant abstract, etc.) becomes publicly available at the “NIH RePORTER” website. 
 
• Dr. Bruijn pointed out that many foundations are funding research.  The system should 
ensure that ATSDR is comfortable with the review of the proposed project. 
 
• Ms. Bledsoe said that if the peer review is pending on a project request, the VA follows up 
with the investigators to ensure that funding will be available. 
 
• Dr. Marcus said that in order to obtain NIH funding, an investigator must prove that there is 
access to specimens.  She asked about a process for providing letters of support for 
proposals, and whether a pre-review system was needed. 
 
• Dr. Bowser said that many investigators have requested letters of support from NEALS so 
that their grant applications can state that they have access to specimens from NEALS.  
There is an abbreviated review by co-chairs of the review committee. 
 
• Dr. Sorenson clarified that the letter of support is qualified.  It does not state that the 
investigators have guaranteed access to samples.  Instead, it indicates that if the project is 
reviewed successfully, there will be access. 
 
• Ms. Bledsoe noted that other repositories provide letters of support indicating that the kinds 
of specimens requested by the investigators are available and describing the process for 
acquiring samples.  Typically, reviewers want to ensure that the applicants have thought 
about the types of samples that they will need and where to find them.  Dr. Bowser added 
that reviewers also want to ensure that enough samples are available. 
 




• Dr. Lonsdale indicated that the NDRI process for letters of support is similar.  They 
determine whether the procurement it technically feasible and whether the tissues are 
available.  They do not make guarantees. 
 
• Dr. Bowser said that NEALS evaluates the proposed methodology.  Some applicants have 
not been willing to disclose the specific protein or gene that will be studied.  Applicants from 
academia and industry were concerned that the review committee might use that 
information for their own purposes.  NEALS created non-disclosure statements that review 
committee members sign for every application. 
 
• Dr. Horton asked for clarification about CDC IRB reviews of proposals. 
 
• Dr. Kaye said that because the biorepository is approved and because the data sent to 
investigators are de-identified, the projects will not need CDC IRB approval.  Applicants will 
indicate whether their institution has reviewed and approved the project or reviewed it and 
determined it not to be Human Subjects research. 
 
• The group discussed aspects of using a website or electronic system to submit applications.  
Dr. Kaye said that the National ALS Registry uses an electronic system to receive 
applications to notify Registry participants about a study.  The biorepository could be 
integrated into this system, but there are potential issues with viruses, so only .pdf files can 
be used. 
 
• Ms. Bledsoe suggested that in its communications, ATSDR could describe reasonable 
amounts and types of tissues.  It is likely that the applications will be better if the 
investigators understand the realm of possibilities at the outset. 
 
• Dr. Horton asked about limiting quantities for researchers.  Dr. Lonsdale said that NDRI 
does not limit quantities; they judge each application on its own merits.  Dr. Kaye noted that 
the volume of tissue requested could factor into the prioritization protocol. 
 
• Mr. Handsfield said that often, the number of samples requested will depend on the kind of 
analysis.  A protocol with a rigorous analysis will require more samples than a descriptive 
study.  He encouraged that anyone requesting samples should have a statistician on the 
investigative team at the outset. 
 
• Dr. Kaye added that the summary should provide justification for the types and numbers of 
samples requested. 
 
Conditions for Release of Samples 
 
• Ms. Steinberg commented that the proposed requirement to send abstracts and manuscripts 
to ATSDR sounded controlling.  Dr. McQuillan noted that NHANES does not make that 
requirement. 
 
• Dr. Kaye said that ATSDR is Congressionally mandated to submit research results to an 
external peer review prior to submitting it to a journal.  Projects that result from the 
biorepository may fall under that rule as well. 
 




• Dr. Sorenson hoped that they could avoid requiring that anyone who publishes research 
results based on samples from the National ALS Biorepository would be required to send 
the manuscripts through ASTDR. 
 
• Ms. Bledsoe said that if that requirement is made, ATSDR should decide what to do with the 
manuscripts.  It may make more sense to require that manuscripts be shared with ATSDR 
after they are accepted for publication. 
 
• Dr. Gubitz indicated that intramural NIH investigators and other NIH employees go through a 
clearance process at NIH. 
 
• Dr. Kasarskis asked whether the intent of this requirement was to ensure that the National 
ALS Biorepository is attributed in the paper.  If that is the case, ATSDR only needs to 
require the author page and acknowledgements.  This approach will not require the 
proposed two-week timeline for abstracts and four-week timeline for manuscripts. 
 
• Dr. Marcus agreed with asking for the manuscript when it is accepted.  The paper can serve 
as a record for how the specimens are used.  She did not think that the paper should be 
subject to review, but it is appropriate to require the investigators to return the publication 
and a lay summary to ATSDR. 
 
• Dr. Bruijn agreed, noting that it is important to remember that the biorepository is a 
partnership with the ALS community.  Lay summaries can serve to promote the 
biorepository.  Researchers will likely welcome that opportunity. 
 
• Dr. Gubitz added that the website could list the publications that have resulted from work 
with the samples.  Dr. Horton said that ATSDR is maintaining a list of papers that resulted 
from the pilot phase of the registry.  He envisioned a similar record of papers from the 
biorepository. 
 
• Mr. Handsfield suggested that this information could be required as part of the annual 
project update.  
 
• Dr. Gwinn hoped that they could streamline the redundant requirements in the documents 
so that they are not burdensome on the investigators.  For instance, some elements in the 
MTA are repeated in the Data Use Agreement.  She asked about preferences for placement 
and timing of the requirements. 
 
• Ms. Bledsoe suggested that the MTA and the Data Use Agreement could be combined, and 
also suggested requiring an institutional official to sign off on the agreements. 
 
Follow Up on Findings 
  
• The group agreed that it is reasonable to expect an annual update on research progress.  
The yearly update could also ask for details about presentations and meetings as well as 
abstracts and articles. 
 
• Mr. Handsfield asked about the time span for the Data Use Agreement, and whether there is 
a time span for renewal or a limit on the number of times that it could be renewed. 
 




• Dr. Jenkins said that the NBDPS Data Use Agreement includes an annual data sharing 
update and requires investigators to resign the agreement annually. 
 
• Mr. Handsfield said that the Centers for Medicare and Medicaid Services (CMS) agreement 
is for five years.  After five years, the agreement is renewed annually and can be renewed 
indefinitely. 
 
• Ms. Bledsoe said that many Data Use Agreements are for the life of the project and do not 
have defined endpoints. 
 
• Dr. Kaye clarified that the intent is to maintain control of the specimens and ensure that they 
are not used for purposes other than the approved project. 
 
• Ms. Bledsoe thought that a time limit may be problematic, as investigators often do not know 
how long it will take for the project to be complete.  As long as the terms in the MTA and 
Data Use Agreement are specific regarding how the specimens and data are used, an 
expiration date may not be necessary. 
 
• Mr. Handsfield noted that a good research project is likely to ask more questions than it 
answers.  A separate document may be needed to amend or extend the MTA and Data Use 
Agreement, or a completely new agreement may be needed if an investigator wants to do 
something new with specimens or data. 
 
• Dr. Bowser described his experience with in investigators who complete the approved 
project and then ask to conduct additional work with any remaining sample.  NEALS 
requires that leftover material should be returned, so these investigators must complete a 
new application in order to use the material in a new way. 
 
• Dr. McQuillan said that NHANES uses an amendment to the agreements in this case.  They 
conduct a review of the new project. 
 
• Ms. Bledsoe asked about the quality of the samples that are returned to NEALS.  Dr. 
Bowser answered that the returned samples are not returned to the repository; rather, they 
are reclassified.  They could be used for pilot assays, for instance.  NEALS is determining 
whether to run QC on the samples.  Ms. Bledsoe clarified that the returned samples may 
have limited utility, but the primary reason for requiring the return of samples is to prevent 
investigators from keeping the samples or giving them to someone else. 
 
• Dr. Lonsdale said that NDRI does not require the return of samples.  Investigators submit a 
Certificate of Destruction of unused samples. 
 
• Dr. McQuillan indicated that NHANES has accepted returned samples and has not 
experienced problems. 
 
• Dr. Gubitz noted that the quality of returned samples will depend on the type of sample, as 
some samples may be more fragile than others. 
 
• Dr. Bowser agreed that the integrity of the sample will depend on what it is used for as well 
as its type.  Because the samples are precious, NEALS asks for them to be returned, even 
though their quality is not assured.  However, everyone does not comply with the 
requirement to return samples. 










• Dr. Kaye pointed out that the Data Use Agreement includes the expectation that 
investigators will submit data from their projects to the registry so that the data are available 
for others to use.  She asked about an appropriate embargo on the information, as the initial 
proposed time was one year, and NHANES has a 60-day time frame. 
 
• Ms. Bledsoe and the group agreed that requiring investigators to return results is a good 
idea, as long as ATSDR is prepared to manage the data when they are submitted. 
 
• Dr. Marcus did not feel that a year would be too long of an embargo, depending on the 
complexity of the research.  NHANES does not release phenotypic information until the 
laboratory data are returned.  That step prevents investigators from sharing data. 
 
• Dr. Bruijn said that it usually does not take one year to publish, especially when researchers 
have been working intimately with data for a long time.  Often, data from one group alone is 
not sufficient, so sharing data from these types of studies is important.  She supported a 
shorter time frame and a collegial sense of sharing. 
 
• Dr. Marcus noted that it takes a great deal of time to analyze, understand, and interpret 
phenotypic data.  She suggested implementing a default time frame, such as six months, 
and giving researchers the option to request and justify a longer embargo period. 
 
• Dr. Kowall said that it is becoming standard to post data sets rapidly to promote rapid 
access to primary data.  There is a priority to publish as well as a responsibility to share. 
 
• Mr. Handsfield pointed out that there are two general schools of statistics:  the Bayesian 
School, which is more likely to work with data to “see what they can find,” and the 
Frequentist School, which tends to design statistical analysis based on the experimental 
design.  Both schools of thought should be accommodated, but it should not take a year or 
more to complete either one. 
 
• Dr. Gwinn commented on the difference between managing data and sharing data.  The 
resources are greater to share data, which should be figured into the cost of managing and 
returning the data. 
 
• Dr. Boylan asked whether an archive will be created and updated with research findings on 
individual de-identified samples. 
 
• Dr. Kaye answered that results and information from each project may be stored as a data 
table, much like Dr. Corriveau’s NINDS resource.  A website will describe ongoing studies, 
but it is not clear how the data will be published and maintained. 
 
• Dr. Antao said that if multiple studies are conducted with the same sample, it may be 
complicated and challenging to append the data tables, especially if different measurements 
are used. 
 
• Dr. Kasarskis suggested that ATSDR create a system for managing the data to build for the 
future and integrate across more extensive data sets.  The uniqueness and added value of 
this biorepository comes from harmonizing it with phenotypic and geographic data from the 
National ALS Registry.  Planning this system and its associated costs will be time well-spent 
as they build this “epidemiological treasure chest.” 
 




• Dr. Brooks agreed and added that the biorepository should plan for the next level of 
harmonization with multiple resources. 
 
• Dr. Gwinn commented that the process will involve more than information technology (IT).  It 
will require curation by a person with subject matter knowledge and the skills needed to 
create a versatile database. 
 
• Dr. Marcus said that if researchers are to be prevented from sharing data with each other, 
then each researcher should have a different set of IDs. 
 
• Mr. Handsfield emphasized that a data management team will be needed, including subject 
matter experts, IT experts, a database administrator, and perhaps a web administrator.  
These costs should be taken into account.  He cautioned that some researchers may 
consider their data to be proprietary. 
 
Making Awards Public 
 
• Dr. Kaye said that ideally, a website will share information about studies and the 
investigators.  The website should be understandable to the public.  She asked for 
suggestions about other efforts, such as actively sharing information with participants. 
 
• Dr. McQuillan cautioned that investigators have not historically been successful at writing lay 
summaries of their work, and it may not be worth asking them to write them.  The 
summaries should be written at the seventh grade level.  Genetics projects are particularly 
difficult to express in simple language. 
 
• Ms. Bledsoe asked about conflict of interest, suggesting that members of the review 
committee should disclose any conflicts.  Investigators should disclose any conflicts that 
were declared to the IRB, but those issues may be best addressed at the institutional level. 
 
Review Process / Committee Makeup 
 
• In addition to the persons proposed for the review committee, Dr. Bruijn suggested adding 
ad hoc representation from the Muscular Dystrophy Association (MDA) and the Amyotrophic 
Lateral Sclerosis Association (ALSA). 
 
• Ms. Bledsoe proposed including a pathologist to review solid tissue in addition to the 
laboratory experts, given that the review will cover a wide range of specimens. 
 
• Dr. Marcus suggested including more than one patient or family member on the committee.  
As they will be the only lay people on the committee, it is important that they will not feel 
intimidated and will feel comfortable speaking up. 
 
  






• Dr. Kaye explained that the review process will be similar to an IRB review.  All members of 
the review committee will receive all of the application materials and rate the proposals.  
Two members of the review committee will be designated as primary and secondary 
reviewers.  They will provide written comments and lead the discussion. 
 
• Dr. Kasarskis suggested that the guidance should define what constitutes a quorum and the 
scoring metrics. 
 
• Dr. Cwik asked for more information about “high priority” versus “low priority,” and what it 
means if a project is approved with low priority. 
 
• Dr. Kaye answered that ATSDR will make the final determination about who receives 
specimens.  The review committee will rank the applications based on the review criteria 
and ATSDR will accept proposals based on the review results and other factors, such as 
whether a proposed project may be duplicative of an ongoing project. 
 
• Dr. Gwinn said that the process could be more transparent.  For instance, publishing a list of 
ongoing projects may reduce duplicative proposals.  Further, the proposals could be divided 
into three levels of priority.  The second level could be pilot-type studies, and the third level 
could be commercially-oriented research.  It is important that the criteria are clear. 
 
• Ms. Bledsoe said that some banks provide a streamlined process for pilot projects.  
Investigators can go through this process to request a small number of samples to test an 
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With input from the group, Dr. Kaye summarized the main points of the day’s deliberations: 
 
Who Can Request Samples 
 
 Research should be about ALS, but ALS should be broadly defined. 
 Applicants can come from academia or industry, but the research must be for purposes of 
knowledge, not profit. 
 Let the scientific review determine the applicability to ALS research. 
 May not want to limit to ALS researchers, but a collaborator that is an ALS researcher 
should be part of the project.  The review committee should determine whether the 
investigative team is qualified to conduct the research.  Researchers who are new to ALS 
may come from other areas, such as immunology. 
 There may be funding and mandate issues associated with using the specimens for 
research other than ALS. 
Overview of Discussion and Recommendations 
 




 The consent form may need revision to accommodate broader research and to not promise 
confidentiality. 
 Samples should be available to the international research community as well as to 
researchers from the United States.  The shipping costs may need to be considered. 
 
Type of Analyses That Can Be Done 
 
 Do not be too prescriptive regarding what should and should not be done, as these issues 
will emerge in the scientific review process.  It is not possible to mandate what future 
advances may be. 
 As part of the negotiations with the investigator, the review committee may consider 
requiring pilot projects or QC on samples.  Returned specimens could be used for this 
activity. 
 
When Can Samples Be Requested? 
 
 Conduct reviews as frequently as possible, on an ongoing or monthly basis, and assess 
proposals in the environment at the time of review.  Researchers may have funder-imposed 
timelines and may be discouraged from using the biorepository if reviews are infrequent. 
 It may be advisable to let the collection mature so that there are sufficient samples and 
sufficient data about them. 
 ATSDR should manage researcher expectations, for instance by announcing when samples 
will be available and whether ongoing samples will available.  It is likely that the samples will 
be available in September 2015, at the end of the pilot study contract. 
 
How To Request Samples 
 
 The full study protocol is unnecessary; a detailed summary and information from the peer 
review should be sufficient. 
 If the peer review from another agency is pending, then ATSDR should follow up with the 
Principal Investigator to see if there is a change of status to ensure that the funding the 
available.  The follow-up could be more proscriptive about what the investigator should 
include in the summary. 
 IRB approval or exemption should be provided. 
 The summary should include preliminary data related to laboratory assays and/or available 
statistical data. 
 ATSDR can create a process for supplying investigators with a letter of support to show 
access to specimens.  The letter can indicate that the specimens are available but will not 
guarantee that the investigator will have access to them.  An abbreviated review of the 
project to ensure that it is appropriate will be necessary to release a letter of support. 
 Applicants will not need CDC IRB review and approval, but they should submit certification 
that the institution where the research will be conducted has reviewed it appropriately.  The 
IRB is not required to be accredited. 
 Investigators can utilize an electronic system for submitting applications.  The system will 
include information on the types of specimens that are available and the sizes of the aliquots 
so that researchers will understand what is available.  The specimens will be aliquoted to 
avoid freezing and thawing the specimens.  The website will also outline the timeframe for 
distributing samples and data to approved investigators. 
 
  




Conditions for Release of Samples 
 
 ATSDR does not need to review abstracts and manuscripts prior to publication.  
Investigators should, however, provide proof that acknowledgement of the sample source is 
included in the manuscript prior to publication.  ATSDR could provide sample language for 
the acknowledgments.  There is little that ATSDR can do other than not provide samples in 
the future, if investigators do not comply with this requirement.  Acknowledging the resource 
builds support for the resource, which the investigators should understand.  These 
requirements and sample language could be included in the MTA and/or Data Use 
Agreement. 
 Investigators could provide citations, presentations, and publications in their annual report. 
 A legal determination on the applicability of ATSDR Peer Review process is needed. 
 Lay summaries of study results will be published on the website. 
 The Data Use Agreement and MTA can be combined into one document, and an 
institutional official and the Principal Investigator should sign it.  The agreements should not 
have an expiration date, but there may be a requirement for renewal or re-signing them.  
This re-signing could be part of the annual review. 





 Samples must be returned to the biorepository at the conclusion of projects. 
 Results will also be returned to the biorepository.  There will be an embargo, perhaps of six 
months, on sharing the information with other investigators so that the researchers have 
time to publish their results.  If justified, researchers can request additional time.  It is 
important that the data community has rapid access to the data. 
 The data returned from researchers will probably not require a new Certificate of Assurance, 
depending on the system and the level of access.  The information is only accessible by a 
very few people; only aggregate data will be available widely. 
 Questions remain regarding data return and sharing, including how to store and curate the 
data.  Managing the data will be a full-time job, especially since multiple data on the same 
patient can be complicated. 
 ATSDR should develop a concept and systems of how to manage data.  The development 
process will need someone with subject matter understanding, and the database team 
should include IT and web administration expertise. 
 To prevent researchers from sharing data with each other, each should have a different set 
of IDs. 
 
Making Awards Public 
 
 ATSDR’s website for the National ALS Registry will expand to include information about the 
projects from the biorepository and their results.  The explanations will be in simple 
language. 
 There was discussion regarding whether ATSDR should require investigators to disclose 
conflicts of interest, or whether that matter should be left to the IRB of the institution that 
houses the research.  There should be a system for reviewers to declare conflicts of interest. 
 
  




Review Process / Committee Makeup 
 
 The review committee will be comprised of the current ATSDR committee, plus a statistician.  
Additionally, a pathologist could be included for review of solid tissue requests, as well as an 
additional lay member and representation from MDA and ALSA. 
 “Quorum” and the scoring metrics will be defined, as well as the prioritization scale.  The 
criteria will be clearly stated. 






At the conclusion of the meeting, the floor was opened for final comments, which were as 
follows: 
 
• Issues related to costs to distribute samples will be addressed in a future meeting focusing 
on feasibility.  Dr. Kaye asked the group whether there might be problems associated with 
charging a fee for pulling and shipping the specimens. 
 
• Dr. Kasarskis felt that the fee would not be a problem, since the samples are not available 
any other way. 
 
• Ms. Bledsoe added that charging for samples may lead applicants to think critically about 
what they are asking for and may improve the science.  There are also costs associated with 
collecting fees.  Cost models are available for these issues. 
 
• Mr. Handsfield added that there could also be costs associated with shipping data with the 
samples, such as the costs of data extraction and media. 
 
• Dr. Horton asked whether the fees are flat per sample, or whether they vary according to the 
sample type. 
 
• Dr. Bowser said that NEALS charges a flat fee, but they do not charge a fee to sites that 
collect samples and participate in the repository.  They charge more for industry. 
 
• Mr. Thomas emphasized that it is not legal to buy and sell tissue, so any fees charged are 
for cost recovery, including shipment, processing, and preservation. 
 
• Ms. Bledsoe said that recent changes to the HIPAA Privacy Rule include requirements 
pertaining to selling data.  Authorization from the patient is required if there will be a sale of 
protected health information (PHI).  There are exceptions for public health and for research.  
The research exception allows costs to be recovered for preparing the data. 
 
• Dr. Kaye said that extracting data is costly and time-consuming, so it will be possible to 
determine a price to defray that cost. 
 
• Mr. Hixon said the party responsible for recovering the money should be identified.  The 









• Dr. Cwik said that funding agencies want to keep costs as low as possible, and while they 
would probably not object to fees associated with samples, the costs should be kept 
reasonable. 
 
• Mr. Thomas recalled the group’s discussion of feedback from researchers about the quality 
of the resource.  There should also be quality indicators for procurement, including an 
assessment of whether environments were maintained and recovery targets were met.  The 
project should be standardized so that it can maintain its goals. 
 
• Dr. Boylan said that one way of ensuring that the sample set is mature is to collect a critical 
mass of samples before they are distributed.  It would be helpful for researchers to know if 
ATSDR has hopes for the types of projects that these samples will be used for, such as 
longitudinal studies that will require both collected time points. 
 
• Dr. Kaye said that the information could be included in the announcement that the 
specimens are available.  The announcement would be on the ATSDR and perhaps in the 
Federal Register. 
 
With no further business posed or questions raised, Dr. Kaye thanked the meeting participants 
and officially adjourned the meeting. 
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